NO20053078L - Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater. - Google Patents

Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.

Info

Publication number
NO20053078L
NO20053078L NO20053078A NO20053078A NO20053078L NO 20053078 L NO20053078 L NO 20053078L NO 20053078 A NO20053078 A NO 20053078A NO 20053078 A NO20053078 A NO 20053078A NO 20053078 L NO20053078 L NO 20053078L
Authority
NO
Norway
Prior art keywords
sup
atropisomers
arylquinolin
derivatives
substituted
Prior art date
Application number
NO20053078A
Other languages
English (en)
Other versions
NO20053078D0 (no
Inventor
Valentin Kala Gribkoff
Vivekananda M Vrudhula
Bireshwar Dasgupta
Christopher G Boissard
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20053078D0 publication Critical patent/NO20053078D0/no
Publication of NO20053078L publication Critical patent/NO20053078L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

Atropisomerer av 3-substituerte 4-arylkinolin-2-on-derivatier som har den generelle formel hvor R, R1, R2, R3, R4 og R5 er som definert her, eller et ikke-toksisk, farmasøytisk akseptabelt salt, solvat eller prodrug derav. Atropisomerene kan modulere høykonduktans kalsium-aktiverte K+-kanaler og er anvendelige ved behandling av lidelser som er responsive overfor åpning av kaliumkanalene. I tillegg kan atropisomerene være stabile, dvs. interkonverteres ikke, i perioder på opptil én måned eller lenger.
NO20053078A 2002-12-23 2005-06-23 Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater. NO20053078L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43616002P 2002-12-23 2002-12-23
PCT/US2003/041548 WO2004058260A1 (en) 2002-12-23 2003-12-18 Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives

Publications (2)

Publication Number Publication Date
NO20053078D0 NO20053078D0 (no) 2005-06-23
NO20053078L true NO20053078L (no) 2005-08-29

Family

ID=32682352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053078A NO20053078L (no) 2002-12-23 2005-06-23 Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.

Country Status (19)

Country Link
US (1) US6939968B2 (no)
EP (1) EP1575589B1 (no)
JP (1) JP2006512378A (no)
KR (1) KR20050102081A (no)
CN (1) CN1750821A (no)
AT (1) ATE472328T1 (no)
AU (1) AU2003300425A1 (no)
BR (1) BR0317679A (no)
CZ (1) CZ2005407A3 (no)
DE (1) DE60333226D1 (no)
IL (1) IL169294A (no)
MX (1) MXPA05006814A (no)
NO (1) NO20053078L (no)
NZ (1) NZ541237A (no)
PL (1) PL377492A1 (no)
RU (1) RU2352563C2 (no)
TR (1) TR200502440T2 (no)
WO (1) WO2004058260A1 (no)
ZA (1) ZA200505077B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679243B (zh) * 2007-04-09 2012-09-26 第一三共株式会社 吡咯衍生物的阻转异构体
US8680116B2 (en) 2009-07-22 2014-03-25 Merck Sharp & Dohme Corp. Quinolinone PDE2 inhibitors
CA2958625C (en) 2013-04-10 2019-05-28 Daiichi Sankyo Company, Limited Crystal of pyrrole derivative and method for producing the same
CN114728177B (zh) * 2019-10-07 2025-06-24 D·E·萧尔研究有限责任公司 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物
BR112022006292A2 (pt) * 2019-10-07 2022-06-28 De Shaw Res Llc Compostos heterobicílicos de arila como bloqueadores de canais de agitador de potássio kv1.3
UY39137A (es) * 2020-04-01 2021-10-29 Fmc Corp Atropisómeros de derivados de piridazinona como herbicidas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1774624C (ru) * 1990-11-11 1995-02-09 Украинская фармацевтическая академия Диэтиламиноэтиламида 1-пропил-2-оксо-4-гидроксихинолин-3-карбоновой кислоты гидрохлорид, проявляющий анестезирующую, противоаритмическую, антиоксидантную, антимикробную и фунгицидную активность
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
SK113299A3 (en) * 1997-02-28 2001-05-10 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists
EP1133474B1 (en) * 1998-12-04 2007-02-21 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
TW562799B (en) * 1999-12-01 2003-11-21 Bristol Myers Squibb Co Preparation of 3-substituted-4-arylquinolin-2-one derivatives
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS

Also Published As

Publication number Publication date
JP2006512378A (ja) 2006-04-13
BR0317679A (pt) 2005-11-29
ATE472328T1 (de) 2010-07-15
WO2004058260A1 (en) 2004-07-15
TR200502440T2 (tr) 2005-10-21
US20040147749A1 (en) 2004-07-29
RU2352563C2 (ru) 2009-04-20
CN1750821A (zh) 2006-03-22
EP1575589A1 (en) 2005-09-21
NO20053078D0 (no) 2005-06-23
US6939968B2 (en) 2005-09-06
DE60333226D1 (de) 2010-08-12
EP1575589B1 (en) 2010-06-30
MXPA05006814A (es) 2005-09-08
IL169294A (en) 2010-11-30
RU2005123046A (ru) 2006-01-20
KR20050102081A (ko) 2005-10-25
ZA200505077B (en) 2006-09-27
NZ541237A (en) 2008-09-26
EP1575589A4 (en) 2008-05-21
CZ2005407A3 (cs) 2005-10-12
AU2003300425A1 (en) 2004-07-22
PL377492A1 (pl) 2006-02-06

Similar Documents

Publication Publication Date Title
NZ510987A (en) 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
MEP52408A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
JO2282B1 (en) Oxazole derivatives
MY135841A (en) Novel benzodioxoles
SE0401971D0 (sv) Piperidne derivatives
BG106013A (en) New compounds and compositions as protease inhibitors
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20044995L (no) Heterosykliske forbindelser
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
ATE477256T1 (de) Thienylverbindungen
SE0402762D0 (sv) Indazole sulphonamide derivatives
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
MXPA05009282A (es) Derivados de anilina sustituidos.
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
NO20053078L (no) Atropisomerer av 3-substituerte-4-arylkinolin-2-on-derivater.
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
SE0203300D0 (sv) Novel Compounds
ATE259813T1 (de) Triazolopyrimidinderivate
DK1056754T3 (da) Phosphatderivater af diaryl-1,3,4-oxadiazolon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application